CCL14 testing to guide clinical practice in patients with AKI: Results from an international expert panel
Urinary C-C motif chemokine ligand 14 (CCL14) is a strong predictor of persistent stage 3 acute kidney injury (AKI). Multiple clinical actions are recommended for AKI but how these are applied in individual patients and how the CCL14 test results may impact their application is unknown. We assembled...
Gespeichert in:
| Veröffentlicht in: | Journal of critical care 2024-08, Vol.82, p.154816-154816, Article 154816 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 154816 |
|---|---|
| container_issue | |
| container_start_page | 154816 |
| container_title | Journal of critical care |
| container_volume | 82 |
| creator | Kellum, John A. Bagshaw, Sean M. Demirjian, Sevag Forni, Lui Joannidis, Michael Kampf, J. Patrick Koyner, Jay L. Kwan, Thomas McPherson, Paul Ostermann, Marlies Prowle, John Ronco, Claudio de la Salle, Julia Schneider, Antoine Tolwani, Ashita Zarbock, Alexander |
| description | Urinary C-C motif chemokine ligand 14 (CCL14) is a strong predictor of persistent stage 3 acute kidney injury (AKI). Multiple clinical actions are recommended for AKI but how these are applied in individual patients and how the CCL14 test results may impact their application is unknown.
We assembled an international panel of 12 experts and conducted a modified Delphi process to evaluate patients at risk for persistent stage 3 AKI (lasting 72 hours or longer). Using a Likert scale, we rated 11 clinical actions based on international guidelines applied to each case before and after CCL14 testing and analyzed the association between the strength and direction of recommendations and CCL14 results.
The strength and direction of clinical recommendations were strongly influenced by CCL14 results (P < 0.001 for the interaction). Nine (82%) recommendations for clinical actions were significantly impacted by CCL14 results (P < 0.001 comparing low to highest CCL14 risk category).
Most recommendations for care of patients with stage 2-3 by an international panel of experts were strongly modified by CCL14 test results. This work should set the stage for clinical practice protocols and studies to determine the effects of recommended actions informed by CCL14.
•Urinary C-C motif chemokine ligand 14 (CCL14) is a newly discovered biomarker for persistent AKI.•We sought to determine how CCL14 test results might change clinical recommendations for AKI.•Twelve experts conducted a modified Delphi process to evaluate patients at risk for persistent AKI.•Nine (82%) recommendations for clinical actions were significantly impacted by CCL14 results. |
| doi_str_mv | 10.1016/j.jcrc.2024.154816 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3048494810</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0883944124003034</els_id><sourcerecordid>3048494810</sourcerecordid><originalsourceid>FETCH-LOGICAL-c335t-1092ad6e483cad31ebe8b295953d3d0bd630ee6782edae31bbc56011ab32d2533</originalsourceid><addsrcrecordid>eNp9kUFv1DAUhC0EotvCH-CALHHhkq1fbGcdxKVaUahYCakqZ8ux3xZH2STYDtB_z1tt4cCBk6Wnb0bjGcZegViDgOayX_c--XUtarUGrQw0T9gKtN5UpgH9lK2EMbJqlYIzdp5zLwRspNTP2Zk0zca0BlYsbrc7ULxgLnG852Xi90sMyP0Qx-jdwOfkfIkeeRz57ErEsWT-M5Zv_OrzzTt-i3kZ6LJP04G7kaiCaSRuGkmMv2ZMhXQjDi_Ys70bMr58fC_Y1-sPd9tP1e7Lx5vt1a7ylK1UINrahQaVkd4FCdih6epWt1oGGUQXGikQKX6NwaGErvO6EQCuk3WotZQX7O3Jd07T94X-ZQ8xexwGCjEt2UqhjGqpLUHom3_Qfloo_XCkGgCpVbshqj5RPk05J9zbOcWDSw8WhD0OYXt7HMIeh7CnIUj0-tF66Q4Y_kr-NE_A-xOA1MWPiMlmT-V6DDGhLzZM8X_-vwHDBZjJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3061135497</pqid></control><display><type>article</type><title>CCL14 testing to guide clinical practice in patients with AKI: Results from an international expert panel</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Kellum, John A. ; Bagshaw, Sean M. ; Demirjian, Sevag ; Forni, Lui ; Joannidis, Michael ; Kampf, J. Patrick ; Koyner, Jay L. ; Kwan, Thomas ; McPherson, Paul ; Ostermann, Marlies ; Prowle, John ; Ronco, Claudio ; de la Salle, Julia ; Schneider, Antoine ; Tolwani, Ashita ; Zarbock, Alexander</creator><creatorcontrib>Kellum, John A. ; Bagshaw, Sean M. ; Demirjian, Sevag ; Forni, Lui ; Joannidis, Michael ; Kampf, J. Patrick ; Koyner, Jay L. ; Kwan, Thomas ; McPherson, Paul ; Ostermann, Marlies ; Prowle, John ; Ronco, Claudio ; de la Salle, Julia ; Schneider, Antoine ; Tolwani, Ashita ; Zarbock, Alexander</creatorcontrib><description>Urinary C-C motif chemokine ligand 14 (CCL14) is a strong predictor of persistent stage 3 acute kidney injury (AKI). Multiple clinical actions are recommended for AKI but how these are applied in individual patients and how the CCL14 test results may impact their application is unknown.
We assembled an international panel of 12 experts and conducted a modified Delphi process to evaluate patients at risk for persistent stage 3 AKI (lasting 72 hours or longer). Using a Likert scale, we rated 11 clinical actions based on international guidelines applied to each case before and after CCL14 testing and analyzed the association between the strength and direction of recommendations and CCL14 results.
The strength and direction of clinical recommendations were strongly influenced by CCL14 results (P < 0.001 for the interaction). Nine (82%) recommendations for clinical actions were significantly impacted by CCL14 results (P < 0.001 comparing low to highest CCL14 risk category).
Most recommendations for care of patients with stage 2-3 by an international panel of experts were strongly modified by CCL14 test results. This work should set the stage for clinical practice protocols and studies to determine the effects of recommended actions informed by CCL14.
•Urinary C-C motif chemokine ligand 14 (CCL14) is a newly discovered biomarker for persistent AKI.•We sought to determine how CCL14 test results might change clinical recommendations for AKI.•Twelve experts conducted a modified Delphi process to evaluate patients at risk for persistent AKI.•Nine (82%) recommendations for clinical actions were significantly impacted by CCL14 results.</description><identifier>ISSN: 0883-9441</identifier><identifier>EISSN: 1557-8615</identifier><identifier>DOI: 10.1016/j.jcrc.2024.154816</identifier><identifier>PMID: 38678981</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acute kidney injury ; Acute Kidney Injury - diagnosis ; Acute Kidney Injury - urine ; Biomarkers ; Biomarkers - urine ; CCL14 ; Chemokines, CC - urine ; Clinical medicine ; Clinical practice guidelines ; Creatinine ; Critical care ; Delphi method ; Delphi Technique ; Female ; Hemodynamics ; Humans ; Likert scale ; Male ; Nephrology ; Patients ; Questionnaires ; Recovery ; Recovery (Medical) ; Urine</subject><ispartof>Journal of critical care, 2024-08, Vol.82, p.154816-154816, Article 154816</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.</rights><rights>2024. The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c335t-1092ad6e483cad31ebe8b295953d3d0bd630ee6782edae31bbc56011ab32d2533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/3061135497?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72341</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38678981$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kellum, John A.</creatorcontrib><creatorcontrib>Bagshaw, Sean M.</creatorcontrib><creatorcontrib>Demirjian, Sevag</creatorcontrib><creatorcontrib>Forni, Lui</creatorcontrib><creatorcontrib>Joannidis, Michael</creatorcontrib><creatorcontrib>Kampf, J. Patrick</creatorcontrib><creatorcontrib>Koyner, Jay L.</creatorcontrib><creatorcontrib>Kwan, Thomas</creatorcontrib><creatorcontrib>McPherson, Paul</creatorcontrib><creatorcontrib>Ostermann, Marlies</creatorcontrib><creatorcontrib>Prowle, John</creatorcontrib><creatorcontrib>Ronco, Claudio</creatorcontrib><creatorcontrib>de la Salle, Julia</creatorcontrib><creatorcontrib>Schneider, Antoine</creatorcontrib><creatorcontrib>Tolwani, Ashita</creatorcontrib><creatorcontrib>Zarbock, Alexander</creatorcontrib><title>CCL14 testing to guide clinical practice in patients with AKI: Results from an international expert panel</title><title>Journal of critical care</title><addtitle>J Crit Care</addtitle><description>Urinary C-C motif chemokine ligand 14 (CCL14) is a strong predictor of persistent stage 3 acute kidney injury (AKI). Multiple clinical actions are recommended for AKI but how these are applied in individual patients and how the CCL14 test results may impact their application is unknown.
We assembled an international panel of 12 experts and conducted a modified Delphi process to evaluate patients at risk for persistent stage 3 AKI (lasting 72 hours or longer). Using a Likert scale, we rated 11 clinical actions based on international guidelines applied to each case before and after CCL14 testing and analyzed the association between the strength and direction of recommendations and CCL14 results.
The strength and direction of clinical recommendations were strongly influenced by CCL14 results (P < 0.001 for the interaction). Nine (82%) recommendations for clinical actions were significantly impacted by CCL14 results (P < 0.001 comparing low to highest CCL14 risk category).
Most recommendations for care of patients with stage 2-3 by an international panel of experts were strongly modified by CCL14 test results. This work should set the stage for clinical practice protocols and studies to determine the effects of recommended actions informed by CCL14.
•Urinary C-C motif chemokine ligand 14 (CCL14) is a newly discovered biomarker for persistent AKI.•We sought to determine how CCL14 test results might change clinical recommendations for AKI.•Twelve experts conducted a modified Delphi process to evaluate patients at risk for persistent AKI.•Nine (82%) recommendations for clinical actions were significantly impacted by CCL14 results.</description><subject>Acute kidney injury</subject><subject>Acute Kidney Injury - diagnosis</subject><subject>Acute Kidney Injury - urine</subject><subject>Biomarkers</subject><subject>Biomarkers - urine</subject><subject>CCL14</subject><subject>Chemokines, CC - urine</subject><subject>Clinical medicine</subject><subject>Clinical practice guidelines</subject><subject>Creatinine</subject><subject>Critical care</subject><subject>Delphi method</subject><subject>Delphi Technique</subject><subject>Female</subject><subject>Hemodynamics</subject><subject>Humans</subject><subject>Likert scale</subject><subject>Male</subject><subject>Nephrology</subject><subject>Patients</subject><subject>Questionnaires</subject><subject>Recovery</subject><subject>Recovery (Medical)</subject><subject>Urine</subject><issn>0883-9441</issn><issn>1557-8615</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kUFv1DAUhC0EotvCH-CALHHhkq1fbGcdxKVaUahYCakqZ8ux3xZH2STYDtB_z1tt4cCBk6Wnb0bjGcZegViDgOayX_c--XUtarUGrQw0T9gKtN5UpgH9lK2EMbJqlYIzdp5zLwRspNTP2Zk0zca0BlYsbrc7ULxgLnG852Xi90sMyP0Qx-jdwOfkfIkeeRz57ErEsWT-M5Zv_OrzzTt-i3kZ6LJP04G7kaiCaSRuGkmMv2ZMhXQjDi_Ys70bMr58fC_Y1-sPd9tP1e7Lx5vt1a7ylK1UINrahQaVkd4FCdih6epWt1oGGUQXGikQKX6NwaGErvO6EQCuk3WotZQX7O3Jd07T94X-ZQ8xexwGCjEt2UqhjGqpLUHom3_Qfloo_XCkGgCpVbshqj5RPk05J9zbOcWDSw8WhD0OYXt7HMIeh7CnIUj0-tF66Q4Y_kr-NE_A-xOA1MWPiMlmT-V6DDGhLzZM8X_-vwHDBZjJ</recordid><startdate>202408</startdate><enddate>202408</enddate><creator>Kellum, John A.</creator><creator>Bagshaw, Sean M.</creator><creator>Demirjian, Sevag</creator><creator>Forni, Lui</creator><creator>Joannidis, Michael</creator><creator>Kampf, J. Patrick</creator><creator>Koyner, Jay L.</creator><creator>Kwan, Thomas</creator><creator>McPherson, Paul</creator><creator>Ostermann, Marlies</creator><creator>Prowle, John</creator><creator>Ronco, Claudio</creator><creator>de la Salle, Julia</creator><creator>Schneider, Antoine</creator><creator>Tolwani, Ashita</creator><creator>Zarbock, Alexander</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K6X</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>202408</creationdate><title>CCL14 testing to guide clinical practice in patients with AKI: Results from an international expert panel</title><author>Kellum, John A. ; Bagshaw, Sean M. ; Demirjian, Sevag ; Forni, Lui ; Joannidis, Michael ; Kampf, J. Patrick ; Koyner, Jay L. ; Kwan, Thomas ; McPherson, Paul ; Ostermann, Marlies ; Prowle, John ; Ronco, Claudio ; de la Salle, Julia ; Schneider, Antoine ; Tolwani, Ashita ; Zarbock, Alexander</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c335t-1092ad6e483cad31ebe8b295953d3d0bd630ee6782edae31bbc56011ab32d2533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acute kidney injury</topic><topic>Acute Kidney Injury - diagnosis</topic><topic>Acute Kidney Injury - urine</topic><topic>Biomarkers</topic><topic>Biomarkers - urine</topic><topic>CCL14</topic><topic>Chemokines, CC - urine</topic><topic>Clinical medicine</topic><topic>Clinical practice guidelines</topic><topic>Creatinine</topic><topic>Critical care</topic><topic>Delphi method</topic><topic>Delphi Technique</topic><topic>Female</topic><topic>Hemodynamics</topic><topic>Humans</topic><topic>Likert scale</topic><topic>Male</topic><topic>Nephrology</topic><topic>Patients</topic><topic>Questionnaires</topic><topic>Recovery</topic><topic>Recovery (Medical)</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kellum, John A.</creatorcontrib><creatorcontrib>Bagshaw, Sean M.</creatorcontrib><creatorcontrib>Demirjian, Sevag</creatorcontrib><creatorcontrib>Forni, Lui</creatorcontrib><creatorcontrib>Joannidis, Michael</creatorcontrib><creatorcontrib>Kampf, J. Patrick</creatorcontrib><creatorcontrib>Koyner, Jay L.</creatorcontrib><creatorcontrib>Kwan, Thomas</creatorcontrib><creatorcontrib>McPherson, Paul</creatorcontrib><creatorcontrib>Ostermann, Marlies</creatorcontrib><creatorcontrib>Prowle, John</creatorcontrib><creatorcontrib>Ronco, Claudio</creatorcontrib><creatorcontrib>de la Salle, Julia</creatorcontrib><creatorcontrib>Schneider, Antoine</creatorcontrib><creatorcontrib>Tolwani, Ashita</creatorcontrib><creatorcontrib>Zarbock, Alexander</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of critical care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kellum, John A.</au><au>Bagshaw, Sean M.</au><au>Demirjian, Sevag</au><au>Forni, Lui</au><au>Joannidis, Michael</au><au>Kampf, J. Patrick</au><au>Koyner, Jay L.</au><au>Kwan, Thomas</au><au>McPherson, Paul</au><au>Ostermann, Marlies</au><au>Prowle, John</au><au>Ronco, Claudio</au><au>de la Salle, Julia</au><au>Schneider, Antoine</au><au>Tolwani, Ashita</au><au>Zarbock, Alexander</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CCL14 testing to guide clinical practice in patients with AKI: Results from an international expert panel</atitle><jtitle>Journal of critical care</jtitle><addtitle>J Crit Care</addtitle><date>2024-08</date><risdate>2024</risdate><volume>82</volume><spage>154816</spage><epage>154816</epage><pages>154816-154816</pages><artnum>154816</artnum><issn>0883-9441</issn><eissn>1557-8615</eissn><abstract>Urinary C-C motif chemokine ligand 14 (CCL14) is a strong predictor of persistent stage 3 acute kidney injury (AKI). Multiple clinical actions are recommended for AKI but how these are applied in individual patients and how the CCL14 test results may impact their application is unknown.
We assembled an international panel of 12 experts and conducted a modified Delphi process to evaluate patients at risk for persistent stage 3 AKI (lasting 72 hours or longer). Using a Likert scale, we rated 11 clinical actions based on international guidelines applied to each case before and after CCL14 testing and analyzed the association between the strength and direction of recommendations and CCL14 results.
The strength and direction of clinical recommendations were strongly influenced by CCL14 results (P < 0.001 for the interaction). Nine (82%) recommendations for clinical actions were significantly impacted by CCL14 results (P < 0.001 comparing low to highest CCL14 risk category).
Most recommendations for care of patients with stage 2-3 by an international panel of experts were strongly modified by CCL14 test results. This work should set the stage for clinical practice protocols and studies to determine the effects of recommended actions informed by CCL14.
•Urinary C-C motif chemokine ligand 14 (CCL14) is a newly discovered biomarker for persistent AKI.•We sought to determine how CCL14 test results might change clinical recommendations for AKI.•Twelve experts conducted a modified Delphi process to evaluate patients at risk for persistent AKI.•Nine (82%) recommendations for clinical actions were significantly impacted by CCL14 results.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38678981</pmid><doi>10.1016/j.jcrc.2024.154816</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0883-9441 |
| ispartof | Journal of critical care, 2024-08, Vol.82, p.154816-154816, Article 154816 |
| issn | 0883-9441 1557-8615 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3048494810 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Acute kidney injury Acute Kidney Injury - diagnosis Acute Kidney Injury - urine Biomarkers Biomarkers - urine CCL14 Chemokines, CC - urine Clinical medicine Clinical practice guidelines Creatinine Critical care Delphi method Delphi Technique Female Hemodynamics Humans Likert scale Male Nephrology Patients Questionnaires Recovery Recovery (Medical) Urine |
| title | CCL14 testing to guide clinical practice in patients with AKI: Results from an international expert panel |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T03%3A06%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CCL14%20testing%20to%20guide%20clinical%20practice%20in%20patients%20with%20AKI:%20Results%20from%20an%20international%20expert%20panel&rft.jtitle=Journal%20of%20critical%20care&rft.au=Kellum,%20John%20A.&rft.date=2024-08&rft.volume=82&rft.spage=154816&rft.epage=154816&rft.pages=154816-154816&rft.artnum=154816&rft.issn=0883-9441&rft.eissn=1557-8615&rft_id=info:doi/10.1016/j.jcrc.2024.154816&rft_dat=%3Cproquest_cross%3E3048494810%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3061135497&rft_id=info:pmid/38678981&rft_els_id=S0883944124003034&rfr_iscdi=true |